These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 17216681

  • 1. Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.
    Silverman SL, Shen W, Minshall ME, Xie S, Moses KH.
    J Rheumatol; 2007 Jan; 34(1):140-4. PubMed ID: 17216681
    [Abstract] [Full Text] [Related]

  • 2. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista (CORE) Investigators.
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [Abstract] [Full Text] [Related]

  • 3. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
    Marcus R, Wang O, Satterwhite J, Mitlak B.
    J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
    [Abstract] [Full Text] [Related]

  • 4. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
    Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L.
    J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
    [Abstract] [Full Text] [Related]

  • 5. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study.
    Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di Matteo L, Scendoni P, Grassi W, Italian Multicentre Osteoporotic Fracture Study Group.
    J Rheumatol; 2007 Jul; 34(7):1551-60. PubMed ID: 17516618
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Osteodensitometry in healthy postmenopausal women.
    Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
    [Abstract] [Full Text] [Related]

  • 11. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures.
    Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J.
    J Bone Miner Res; 2000 Jul; 15(7):1384-92. PubMed ID: 10893688
    [Abstract] [Full Text] [Related]

  • 12. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J.
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
    Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA.
    J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
    [Abstract] [Full Text] [Related]

  • 14. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
    Kanis JA, Johansson H, Oden A, McCloskey EV.
    Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ.
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [Abstract] [Full Text] [Related]

  • 19. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
    Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Stock JL.
    Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
    [Abstract] [Full Text] [Related]

  • 20. Raloxifene: results from the MORE study.
    Agnusdei D, Iori N.
    J Musculoskelet Neuronal Interact; 2000 Dec; 1(2):127-32. PubMed ID: 15758505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.